Clinical trials: gemcitabine hydrochloride
Cancer
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
This is a Phase IIa, open-label, single-arm, multi-center study to evaluate the efficacy and safety of orally administered MEK inhibitor trametinib as the second line in subjects with advanced or metastatic biliary tract cancers…
- Trial name
- NCT01943864
- Testing
- Trametinib (single tablet), Trametinib (Multiple tablet)
- Where
- 5 sites in Japan
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Stage IIIA Non-Small Cell Lung Cancer
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) works in predicting response to chemotherapy in patients with stage IIIA non-small cell lung cancer…
- Trial name
- NCT02607423
- Testing
- Cisplatin, Computed Tomography, Docetaxel
- Where
- United States
- Sponsor
- ECOG-ACRIN Cancer Research Group
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
This phase II trial tests how well radiation therapy with pembrolizumab and chemotherapy (paclitaxel or nab-paclitaxel or carboplatin and gemcitabine) works in treating patients with PD-L1 positive triple negative breast cancer…
- Trial name
- NCT06492759
- Testing
- Radiation Therapy, Pembrolizumab, Nab-paclitaxel
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Emory University
Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of gemcitabine hydrochloride, clofarabine, and busulfan before donor stem cell transplant and to see how well it works in treating patients with B-cell or T-cell…
- Conditions
- Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01701986
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Bladder (Urothelial, Transitional Cell) Cancer
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.
- Trial name
- NCT06696742
- Testing
- Clostridium Butyricum Tablets, Cisplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pancreatic Adenocarcinoma
Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
The research trial is testing the experimental treatment MSC1936369B in combination with Gemcitabine, in subjects with metastatic pancreatic adenocarcinoma.
- Trial name
- NCT01016483
- Testing
- Pimasertib, Gemcitabine
- Where
- 2 sites in United States, Germany
- Volunteers
- 141 people
- Sponsor
- EMD Serono
Unspecified Adult Solid Tumor, Protocol Specific
Carboplatin and Gemcitabine in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00021346
- Testing
- carboplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Fox Chase Cancer Center
Non-Muscle Invasive Bladder Cancer
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved drug nadofaragene firadenovec will be compared to usual care with…
- Trial name
- NCT06929286
- Testing
- Nadofaragene Firadenovec, Gemcitabine, Docetaxel
- Where
- 9 sites in United States
- Volunteers
- 125 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Non-Hodgkin's
Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
This is a pilot study to determine the overall survival rate and toxicities of obinutuzumab given with GDP chemotherapy for relapsed or refractory CD20+ aggressive non-Hodgkin lymphoma.
- Trial name
- NCT02750670
- Testing
- Obinutuzumab, Gemcitabine, Dexamethasone
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
This phase I/II trial is studying the side effects and best dose of sorafenib, gemcitabine, and capecitabine and to see how well they work in treating patients with unresectable and/or metastatic kidney cancer.
- Conditions
- Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT00121251
- Testing
- Capecitabine, Gemcitabine Hydrochloride, Sorafenib Tosylate
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer Recurrent
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes in women with FIGO stage III and IV epithelial…
- Trial name
- NCT03657966
- Testing
- DCVAC/OvCa, Standard of Care Chemotherapy
- Where
- 8 sites in Czechia
- Volunteers
- 33 people
- Sponsor
- SOTIO a.s.
Non Small Cell Lung Cancer, BRCA1 Mutation
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma
Primary objective: · Progression free survival. Secondary objectives: Assess Overall survival of both treatment groups. Assess Tumor response rate using RECIST criteria Assess Toxicity profile of patients enrolled in the study.
- Trial name
- BREC (NCT00617656)
- Testing
- Cisplatin, Docetaxel, Gemcitabine, Cisplatin, Docetaxel, Cisplatin
- Where
- 44 sites in Spain
- Volunteers
- 382 people
- Sponsor
- Spanish Lung Cancer Group
Pancreatic Adenocarcinoma
Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer
The objective of this study is to improve survival by the addition of anakinra to the chemotherapy combination of nab-paclitaxel, gemcitabine, and cisplatin in patients with resectable or potentially resectable pancreatic…
- Trial name
- NCT02550327
- Testing
- Nab-paclitaxel, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baylor Research Institute
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033241
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- OSI Pharmaceuticals
Pancreatic Cancer
A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy in a 28-day schedule.The secondary purpose is to assess the efficacy and…
- Trial name
- NCT03301805
- Testing
- BLEX 404
- Volunteers
- 40 people
- Sponsor
- Rgene Corporation
Pancreatic Cancer, Pancreatic Adenocarcinoma
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in…
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
- Trial name
- NCT02723331
- Testing
- Nab paclitaxel, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Non-Small Cell Lung Cancer
Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
This study is being done to determine the overall progression-free survival (PFS) in patients with advanced or metastatic (Stage IIIB - pleural effusion/IV), non-squamous histology NSCLC treated with metronomic chemotherapy plus…
- Trial name
- NCT00655850
- Testing
- Paclitaxel, Gemcitabine, Avastin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Alabama at Birmingham
Nasopharyngeal Carcinoma
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
This study aims to explore a new, more effective and tolerable treatment regimen for patients with advanced recurrent/metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05854849
- Testing
- Camrelizumab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Lung Cancer
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
To evaluate the overall survival (OS) of patients with advanced squamous cell lung cancer receiving the combination of gemcitabine/carboplatin either with or without Iniparib.
- Trial name
- ECLIPSE (NCT01082549)
- Testing
- gemcitabine/carboplatin, gemcitabine/carboplatin plus Iniparib
- Where
- 142 sites in United States, Belgium and 12 more
- Volunteers
- 780 people
- Sponsor
- Sanofi
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with…
- Trial name
- Carolyn-USA (NCT07049055)
- Testing
- E-EDV-D682, EDV-GC, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 144 people
- Sponsor
- Engeneic Pty Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.